Actinium Pharma Analyst Ratings
Actinium Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 247.52% | B. Riley Securities | → $20 | Reiterates | Buy → Buy |
| 09/07/2023 | 768.81% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 09/06/2023 | 101.56% | HSBC | → $11.6 | Initiates Coverage On | → Buy |
| 08/15/2023 | 768.81% | HC Wainwright & Co. | $53 → $50 | Maintains | Buy |
| 05/16/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | Buy → Buy |
| 04/20/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 02/21/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/07/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 10/31/2022 | 212.77% | B. Riley Securities | $16 → $18 | Maintains | Buy |
| 10/31/2022 | 820.94% | HC Wainwright & Co. | $45 → $53 | Maintains | Buy |
| 09/08/2022 | 247.52% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 08/25/2022 | 178.02% | B. Riley Securities | → $16 | Initiates Coverage On | → Buy |
| 08/03/2021 | 681.93% | HC Wainwright & Co. | $57 → $45 | Maintains | Buy |
| 04/01/2021 | 890.44% | HC Wainwright & Co. | $65 → $57 | Maintains | Buy |
| 06/04/2020 | -47.87% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/03/2023 | 247.52% | B.莱利证券 | →$20 | 重申 | 购买→购买 |
| 09/07/2023 | 768.81% | HC Wainwright公司 | →$50 | 重申 | 购买→购买 |
| 09/06/2023 | 101.56% | 汇丰银行 | →$11.6 | 开始承保 | →购买 |
| 2023年08月15日 | 768.81% | HC Wainwright公司 | $53→$50 | 维护 | 买 |
| 2023年05月16日 | 820.94% | HC Wainwright公司 | →$53 | 重申 | 购买→购买 |
| 04/20/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →购买 |
| 02/21/2023 | - | 威廉·布莱尔 | 评级下调 | 跑赢→市场表现 | |
| 02/21/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →购买 |
| 02/07/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →购买 |
| 2022年10月31日 | 212.77% | B.莱利证券 | $16→$18 | 维护 | 买 |
| 2022年10月31日 | 820.94% | HC Wainwright公司 | $45→$53 | 维护 | 买 |
| 09/08/2022 | 247.52% | 康托·菲茨杰拉德 | →$20 | 开始承保 | →超重 |
| 2022年08月25日 | 178.02% | B.莱利证券 | →$16 | 开始承保 | →购买 |
| 08/03/2021 | 681.93% | HC Wainwright公司 | $57→$45 | 维护 | 买 |
| 04/01/2021 | 890.44% | HC Wainwright公司 | $65→$57 | 维护 | 买 |
| 06/04/2020 | -47.87% | HC Wainwright公司 | →$3 | 开始承保 | →购买 |
What is the target price for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的目标价是多少？
The latest price target for Actinium Pharma (AMEX: ATNM) was reported by B. Riley Securities on October 3, 2023. The analyst firm set a price target for $20.00 expecting ATNM to rise to within 12 months (a possible 247.52% upside). 11 analyst firms have reported ratings in the last year.
B.Riley Securities于2023年10月3日报告了Actdium Pharma(美国证券交易所代码：ATNM)的最新目标价。这家分析公司将目标价定为20美元，预计ATNM将在12个月内上涨至(可能上涨247.52%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的最新分析师评级是多少？
The latest analyst rating for Actinium Pharma (AMEX: ATNM) was provided by B. Riley Securities, and Actinium Pharma reiterated their buy rating.
Actdium Pharma(美国证券交易所代码：ATNM)的最新分析师评级由B.Riley Securities提供，Actdium Pharma重申其买入评级。
When is the next analyst rating going to be posted or updated for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharma was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查看公开的财务报表，与Actdium Pharma的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Actdium Pharma的上一次评级是在2023年10月3日提交的，因此您应该预计下一次评级将在2024年10月3日左右的某个时候提供。
Is the Analyst Rating Actinium Pharma (ATNM) correct?
分析师对Actdium Pharma(ATNM)的评级正确吗？
While ratings are subjective and will change, the latest Actinium Pharma (ATNM) rating was a reiterated with a price target of $0.00 to $20.00. The current price Actinium Pharma (ATNM) is trading at is $5.76, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Actdium Pharma(ATNM)评级被重申，目标价在0.00美元至20.00美元之间。Actdium Pharma(ATNM)目前的交易价格为5.76美元，在分析师的预测范围内。